Omnicare Clinical Research announced today that it has expanded its global footprint to include an office in Sweden.
OMNICARE CLINICAL RESEARCH OPENS OFFICE IN SWEDEN
King of Prussia, PA-11 August 2008-Omnicare Clinical Research announced today that it has expanded its global footprint to include an office in Sweden. The office is located at Kista Science Tower, Unit B1272, Färögatan 33, 164 51 Kista, Sweden.
“Omnicare Clinical Research continues to expand its worldwide presence through the opening of this new Swedish facility,” said Dr. Dale Evans, President and CEO. “We are committed to the Scandinavian marketplace, where we already have offices in Denmark and Finland. We’re looking forward to future growth and continued success with our partners in the region.”
About Omnicare Clinical Research
Headquartered in King of Prussia, PA, Omnicare Clinical Research provides clinical
development services to pharmaceutical, biotechnology and medical device companies through
its office locations in 31 countries worldwide. As a premier Phase I-IV contract research
organization, Omnicare Clinical Research features diverse therapeutic expertise and a
comprehensive scope of clinical service offerings. Additionally, the company is an industry
leader in geriatrics-focused drug studies. Omnicare Clinical Research focuses on providing clients with a superior drug development experience through strong project management, exceptional service and proactive solutions. The company is a subsidiary of Omnicare, Inc., a leading provider of pharmacy services to long-term care facilities and other chronic care settings comprising nearly 1.4 million beds in 47 states (NYSE: OCR).
www.OmnicareCR.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.